NeuroMed offers Brainsway Deep TMS treatment for Depression and other conditions, including: PTSD, OCD, Autism Spectrum Disorders, ADHD and Chronic Pain.
Brainsway’s technology has been enthusiastically embraced by the international academic community, and has participated in over 60 clinical studies in leading institutions worldwide.
The Brainsway Deep TMS treatment was cleared by the FDA for treatment of a wide range of patients, suffering from mild to severe depression, who did not benefit from antidepressants. Brainsway’s technology is based on a patent registered by the U.S. National Institutes of Health (NIH).
NeruoMed is happy to be a preferred provider of Brainsway Deep TMS due to the many advantages this device offers over other “superficial” or rTMS devices. The device tends to be more comfortable and takes half of the time of other TMS interventions. Patients spend 20 minutes each visit in the treatment compared to 40 minutes or more in TMS machines. Your head is not restrained to the chair and in fact rather than using a dental style chair patients relax in a club style chair like you might choose for your own home. The Brainsway Deep TMS also provides greater treatment flexibility and has broad indications for conditions beyond the treatment of depression to include: PTSD, OCD, Anxiety, Autism Spectrum Disorders, ADHD, and Chronic Pain.
In a multi-center study, Brainsway Deep TMS depression treatment was tested for treating major depressive disorder patients who previously used antidepressants unsuccessfully. In this multicenter study, enrolling 230 patients, Brainsway’s depression treatment was found to bring significant improvement to patients. Following this study, the FDA cleared Brainsway Deep TMS for the treatment of depression patients who did not benefit from any number of previous medication treatments.
In an 18-week study, following 4 weeks of Brainsway Deep TMS treatment, a significant decrease was found in depressive symptoms (based on Hamilton Depression Rating Scale) and maintained throughout the study. The procedure was generally well tolerated and no adverse events were reported. The results suggest that H-coil deep-TMS administered continuation treatment can help maintain an antidepressant effect for 18 weeks, following 4 weeks of acute treatment.
Brainsway Deep TMS depression treatment was clinically tested in a trial at McGill University in Canada enrolling treatment resistant depression patients. Response (signifying an improvement of at least 50% in depression related symptoms) and remission (HDRS-21 scores, which rate depressive symptoms, lower than 10) rates were an impressive 70.6 and 41.2%, respectively. Depression, anxiety ratings and quality of life scores significantly improved as well. The study showed that Deep TMS therapy improves depressive and anxious symptoms in patients with severe, treatment resistant depression. Furthermore, Deep TMS treatment was not associated with serious adverse events.